![](/img/cover-not-exists.png)
Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial
Yardley, Denise A., Raefsky, Eric, Hainsworth, John D., Burris, Howard A., Priego, Victor, Inclan, AlejandroVolume:
148
Language:
english
Journal:
Breast Cancer Research and Treatment
DOI:
10.1007/s10549-014-3189-y
Date:
December, 2014
File:
PDF, 193 KB
english, 2014